Calling All MA Plans: Three New Stars Lawsuits
We are officially counting on our fingers and toes now!
Three new Medicare Advantage (MA) Stars lawsuits. Currently, we have 18 lawsuits and 15 distinct plans which have sued the Centers for Medicare and Medicaid Services (CMS) over either their Star Year (SY) 2026 or 2027 ratings. Four for 2026 and 14 for 2027.
Molina Healthcare sued CMS over its 2027 MA Star Ratings on Nov. 13 in D.C. federal district court, alleging improper data use cost the insurer $140 million in bonus payments. Molina cites CMS’ decision to use a favorable method to calculate Clover Health’s 2026 and 2027 scores. The company wants the court to declare it unlawfully included 14 measures when calculating its ratings.
UPMC Health Plan filed its suit in the same court on Nov. 13 as well over 2027 ratings. It challenges 19 measures. UPMC alleges Administrative Procedure Act (APA) violations by using the 19 measures. UPMC says the move cut its eligible quality bonus payments and rebate retention by roughly $41 million for the 2028 payment year.
Point32Health, parent of Tufts Health Plan, filed Nov. 10 in D.C. federal court, challenging 10 measures on rulemaking grounds. Its two contracts received 4 and 3.5 stars, which it says should have been 4.5 and 4. The insurer estimates roughly $41.4 million in lost revenue.
Additional article: https://www.modernhealthcare.com/insurance/mh-molina-medicare-advantage-star-ratings-lawsuit/
#medicareadvantage #cms #quality #stars
Trump Pushes Anti-Fraud Rule
The Centers for Medicare and Medicaid Services (CMS) proposed a massive anti-fraud rule touching most areas of healthcare offerings. It says the rule will produce $90 billion in savings over a decade across Medicare, Medicaid and the health insurance exchanges.
The rule focuses on reporting requirements, strict penalties, and removal of providers from government programs.
Part of the rule includes re-establishing a Risk Adjustment Data Validation (RADV) rule with controversial extrapolation with retroactivity back to 2018. An FFS adjuster would also be eliminated. CMS estimates RADV audits would collect $9 billion per payment year in overpayments.
Medicare Advantage (MA) plans would have enhanced fraud reporting requirements.
Additional articles: https://www.modernhealthcare.com/politics-regulation/mh-cms-crush-rule-medicare-medicaid-fraud/ and https://www.cms.gov/newsroom/fact-sheets/comprehensive-regulations-uncover-suspicious-healthcare-crush-proposed-rule-cms-6098-p
#fwa #cms #medicareadvantage #medicaid #exchanges #schip
Mixed Record On Preemption For State PBM Laws
Interesting article on the mixed legal record on arguing self-insured ERISA preemption when it comes to pharmacy benefits manager (PBM) reforms. Some courts, including the Supreme Court, have ruled state laws should not be set aside due to preemption, while others have sided with federal law’s applicability.
#erisa #pbms
https://www.modernhealthcare.com/insurance/mh-state-pbm-laws-erisa-preemption-lawsuits
AI Healthcare Investment Big, But Struggling
Menlo Partners finds that healthcare remains artificial intelligence’s (AI) biggest vertical, with investments ballooning to $3.7 billion, up more than double the past year. The firm says healthcare provider organizations are looking to deploy AI in new areas to reduce costs and facilitate clinical interventions.
At the same time, Google Cloud reports that unpredictable costs and mounting technical complexity are holding back scale. About 60% of surveyed healthcare executives say they’ve faced integration and deployment challenges in trying to move from pilot to enterprise implementation. About 40% cite unpredictable costs as a reason for backing away. Just 30% report successfully scaling advanced or agentic AI across their operations. About 40% also said protection of sensitive data is an essential consideration. Survey respondents want full visibility into an AI tool’s governance process and customization.
Additional article: https://www.healthcaredive.com/news/healthcare-struggles-to-scale-ai-past-pilot-stage-google-report/874609/
#ai #healthcare
CVS Pushes Big Pharma On GLP-1s
Interesting tactic from CVS Health on GLP-1s. A new white paper pushes the expansion of GLP-1 medications by showing the drugs are associated with better health outcomes and lower costs, including fewer hospitalizations. The problem: they remain very expensive and broad expansion is being hobbled.
CVS says employers and other payers would save if the pricing dropped to $350 per month or less. Currently, employers pay between $617 and $766 a month for GLP-1s. Employers and others have cut back on coverage due to surging costs. Those costs wipe out any near-term savings.
The white paper will turn up the heat on the two biggest GLP-1 producers, Eli Lilly and Novo Nordisk (now just Novo).
#weightlossdrugs #glp1s
https://www.healthcaredive.com/news/glp-1s-save-money-priced-350-month-cvs-lilly-novo/874705
— Marc S. Ryan
